REG - ConvaTec Group PLC - Board Committee Changes

ConvaTecAnnouncement

27/01/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220127:nRSa8553Za&default-theme=true

RNS Number : 8553Z  ConvaTec Group PLC  27 January 2022

ConvaTec Group Plc

Board Committee Changes

 

Reading, United Kingdom - 27 January 2022

 

ConvaTec Group Plc ("ConvaTec" or "the Company") is pleased to announce that
Professor Constantin Coussios, a Non-Executive Director of the Company, has
today been appointed as a member of the Company's Remuneration Committee and
Nomination Committee.

 

This announcement is made in accordance with Listing Rule 9.6.11R (3).

Enquiries:

Analysts and Investors

Kate Postans, Vice President, Investor
Relations
                +44(0)7826 447 807

ir@convatec.com (mailto:ir@convatec.com)

Media

Buchanan: Chris
Lane
                                +44(0)207 466
5000

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec Group Plc
ConvaTec is a global medical products and technologies company focused on
therapies for the management of chronic conditions, with leading market
positions in advanced wound care, ostomy care, continence and critical care,
and infusion care. Our vision, which encompasses our purpose, is: Pioneering
trusted medical solutions to improve the lives we touch. Our products provide
a range of clinical and economic benefits including infection prevention,
protection of at-risk skin, improved patient outcomes and reduced total cost
of care. To learn more about ConvaTec, please visit www.convatecgroup.com
(http://www.convatecgroup.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUBRRRUVUAUAR